Log in | Register

Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients

Mario Tumbarello| Gennaro De Pascale| Enrico Maria Trecarichi| Teresa Spanu| Federica Antonicelli| Riccardo Maviglia| Mariano Alberto Pennisi| Giuseppe Bello| Massimo Antonelli
Original
Volume 39, Issue 4 / April , 2013

Pages 682 - 692

Abstract

Purpose

Our aim was to identify the clinical profile of intensive care unit (ICU) patients with Pseudomonas aeruginosa (PA) pneumonia and the impact on ICU mortality and duration of mechanical ventilation (MV) of multidrug resistance (MDR) in the PA isolate and inadequate initial antibiotic therapy (IIAT).

Methods

We conducted a retrospective analysis of data prospectively collected in the 18-bed general ICU of a major teaching hospital in Rome, Italy. The study cohort consisted of 110 adult patients with culture-confirmed PA pneumonia consecutively diagnosed in 2008–2010. ICU survivor and nonsurvivor groups were compared to identify factors associated with ICU mortality.

Results

In 42 (38 %) of the 110 cases of PA pneumonia analyzed, the PA isolate was MDR. Fifty-six (50.9 %) of the patients received IIAT, and 49 (44.5 %) died in ICU. In logistic regression analysis, IIAT, diabetes mellitus, higher Simplified Acute Physiology Score (SAPS) II scores, and older age were independently associated with ICU mortality. Among survivors, those who received IIAT or had MDR PA pneumonia had significantly longer median (interquartile ranges, IQR) periods of post-pneumonia onset MV (16.5 [14.5–20] and 15 [12–18] days, respectively) compared with those whose initial therapy was adequate (8 [6–13] days, P < 0.001) and those whose infections were caused by non-MDR PA (10.5 [6.5–13] days, P = 0.01).

Conclusions

Our findings highlight the importance of IIAT as a risk factor for mortality in ICU patients with PA pneumonia. MDR in the PA isolate, like IIAT, can significantly increase the need for MV.

Keywords

References

  1. Goossens H (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 9:980–983
    • View reference on PubMed
    • View reference on publisher's website
  2. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK, Canadian Critical Care Trials Group (2008) Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 23:18–26
    • View reference on PubMed
    • View reference on publisher's website
  3. Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81–S87
    • View reference on PubMed
    • View reference on publisher's website
  4. Torres A, Ewig S, Lode H, Carlet J (2009) Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 35:9–29
  5. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578
    • View reference on PubMed
    • View reference on publisher's website
  6. Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y (2010) In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 36:513–522
    • View reference on PubMed
    • View reference on publisher's website
  7. Sun HY, Fujitani S, Quintiliani R, Yu VL (2011) Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139:1172–1185
    • View reference on PubMed
    • View reference on publisher's website
  8. Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, DE Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, Cauda R, Bassetti M (2011) Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 139:1740–1749
    • View reference on PubMed
    • View reference on publisher's website
  9. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH (2008) Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281–287
    • View reference on PubMed
    • View reference on publisher's website
  10. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J (2007) Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35:1888–1895
    • View reference on PubMed
    • View reference on publisher's website
  11. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281–288
    • View reference on PubMed
    • View reference on publisher's website
  12. Montravers P, Fagon JY, Chastre J, Lecso M, Dombret MC, Trouillet JL, Gibert C (1993) Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 147:38–44
    • View reference on PubMed
    • View reference on publisher's website
  13. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B, Outcomerea Study Group (2006) Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129:110–117
    • View reference on PubMed
    • View reference on publisher's website
  14. Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J (2009) Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 43:28–35
    • View reference on PubMed
    • View reference on publisher's website
  15. Kaminski C, Timsit JF, Dubois Y, Zahar JR, Garrouste-Orgeas M, Vesin A, Azoulay E, Feger C, Dumenil AS, Adrie C, Cohen Y, Allaouchiche B, OUTCOMEREA study group (2011) Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care 15:R112
    • View reference on PubMed
    • View reference on publisher's website
  16. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J (2006) Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 32:1970–1978
  17. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34:1047–1054
    • View reference on PubMed
    • View reference on publisher's website
  18. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K (2008) Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178:513–519
    • View reference on PubMed
    • View reference on publisher's website
  19. Giantsou E, Manolas K (2011) Superinfections in Pseudomonas aeruginosa ventilator-associated pneumonia. Minerva Anestesiol 77:964–970
    • View reference on PubMed
  20. Venier AG, Gruson D, Lavigne T, Jarno P, L’hériteau F, Coignard B, Savey A, Rogues AM, REA-RAISIN group (2011) Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect 79:44–48
    • View reference on PubMed
    • View reference on publisher's website
  21. Rello J, Allegri C, Rodriguez A, Vidaur L, Sirgo G, Gomez F, Agbaht K, Pobo A, Diaz E (2006) Risk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure. Anesthesiology 105:709–714
    • View reference on PubMed
    • View reference on publisher's website
  22. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM (1991) Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 143:1121–1129
    • View reference on PubMed
  23. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
    • View reference on PubMed
    • View reference on publisher's website
  24. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758
    • View reference on PubMed
    • View reference on publisher's website
  25. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eighteenth Informational Supplement. 2008, M100-S18. Wayne, PA
  26. Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327
    • View reference on PubMed
    • View reference on publisher's website
  27. Fujitani S, Sun HY, Yu VL, Weingarten JA (2011) Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 139:909–919
    • View reference on PubMed
    • View reference on publisher's website
  28. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW (2010) Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54:3717–3722
    • View reference on PubMed
    • View reference on publisher's website
  29. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68–74
    • View reference on PubMed
    • View reference on publisher's website
  30. Damas P, Layios N, Seidel L, Nys M, Melin P, Ledoux D (2011) Severity of ICU-acquired pneumonia according to infectious microorganisms. Intensive Care Med 37:1128–1135
  31. Kuti EL, Patel AA, Coleman CI (2008) Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 23:91–100
    • View reference on PubMed
    • View reference on publisher's website
  32. Vincent JL (2000) Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 26(Suppl 1):S3–S8
  33. Nordmann P, Naas T, Poirel L (2011) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798
    • View reference on PubMed
    • View reference on publisher's website
  34. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22th Informational Supplement. 2012, M100-S22. Wayne, PA
  35. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52:813–821
    • View reference on PubMed
    • View reference on publisher's website
  36. Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, De Pascale G, Proli EM, Cauda R, Cicchetti A, Fadda G (2010) Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 54:4085–4091
    • View reference on PubMed
    • View reference on publisher's website
  37. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA (2010) Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 54:109–115
    • View reference on PubMed
    • View reference on publisher's website
  38. Shorr AF, Combes A, Kollef MH, Chastre J (2006) Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 34:700–706
    • View reference on PubMed
    • View reference on publisher's website
  39. Shorr AF, Micek ST, Kollef MH (2008) Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 36:2335–2340
    • View reference on PubMed
    • View reference on publisher's website
  40. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH (2011) Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 39:46–51
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement